Taysha (TSHA) Form 144 Filed for 200,000-Share Sale via Jefferies

Rhea-AI Filing Summary

Taysha Gene Therapies, Inc. (TSHA) filing a Form 144 notifies a proposed sale of 200,000 common shares through Jefferies LLC on 09/10/2025 with an aggregate market value of $652,000.00. The filing lists total shares outstanding as 272,794,885. Securities to be sold were acquired via vested awards: 158,850 shares from a 01/02/2024 RSU award and 37,106 plus 4,044 shares from vested option grants on 05/31/2023. The form also discloses a prior sale of 57,054 shares on 08/21/2025 for $162,603.90. Several standard filer and issuer contact fields in the notice are blank or not provided.

Positive

• Clear disclosure of the proposed sale quantity (200,000 shares) and broker (Jefferies LLC)
• Acquisition details provided: vested RSU (01/02/2024) and vested option grants (05/31/2023) with share counts

Negative

• Filer and issuer contact fields are blank or not provided in the notice, limiting verification
• Insider sales reported including a recent prior sale of 57,054 shares on 08/21/2025 (gross proceeds $162,603.90)

Insights

Securities Analyst

TL;DR Routine insider sale disclosure; transaction size and acquisition sources are clearly stated with prior sale history.

The Form 144 documents a proposed sale of 200,000 common shares via Jefferies at an indicated aggregate market value of $652,000, and identifies the origin of the shares as vested RSUs and vested options granted by Taysha Gene Therapies, Inc. The filing also notes a recent sale of 57,054 shares for $162,603.90. This is a standard regulatory notice enabling an insider to sell company stock under Rule 144; the notice itself does not disclose any new operational or financial performance information about the issuer.

Corporate Governance Expert

TL;DR Proper disclosure of planned insider sale and prior sales, but key filer contact details are missing in the document.

The filing provides necessary disclosure about the securities to be sold, their acquisition dates and nature (vested RSU and vested stock options), and lists the broker and planned sale date. It also contains a representation regarding absence of undisclosed material adverse information. However, multiple standard filer and issuer contact fields appear blank, which could hinder follow-up or verification by stakeholders reviewing the notice.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Avenue 4th Floor New York NY 10022	200000	652000.00	272794885	09/10/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/02/2024	Vested RSU Award	Taysha Gene Therapies, Inc.			158850	01/02/2024	N/A
Common	05/31/2023	Vested Stock Option Grant	Taysha Gene Therapies, Inc.			37106	05/31/2023	N/A
Common	05/31/2023	Vested Stock Option Grant	Taysha Gene Therapies, Inc.			4044	05/31/2023	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Sukumar Nagendran 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247	Common	08/21/2025	57054	162603.90

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the TSHA Form 144 disclose about the proposed sale?

The notice reports a proposed sale of 200,000 common shares through Jefferies LLC on 09/10/2025 with an aggregate market value of $652,000.00.

How were the shares being sold by the insider acquired?

The filing shows the shares were acquired via a vested RSU award on 01/02/2024 (158,850 shares) and vested stock option grants on 05/31/2023 (37,106 and 4,044 shares).

Does the filing show any recent prior sales by the same person?

Yes. It discloses a sale of 57,054 common shares on 08/21/2025 for gross proceeds of $162,603.90.

What is the total number of shares outstanding reported in the filing?

The filing lists 272,794,885 shares outstanding for the issuer.

Is all issuer and filer contact information provided in this Form 144?

No. Several filer and issuer contact fields in the notice are blank or not provided in the supplied content.